Empower has commenced phase one and phase two COVID-19 testing in Oregon for existing and new patients, and supports Oregon ballot IP34 by collecting signatures in its Portland wellness clinic to advance Oregon’s psilocybin therapy initiative
VANCOUVER B.C. June 10th, 2020 – EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) (“Empower” or the “Company”), a vertically integrated life sciences company, is pleased to announce that Empower has initiated phase one and phase two COVID-19 testing in its Portland, OR clinic. In addition, the Company, in its Portland clinic is successfully collecting signatures for the IP34 ballot for the psilocybin therapy initiative.
“Our team has performed COVID-19 tests for groups and individuals both remotely and inside our clinics as part of our testing program. With national rates of COVID-19 currently spiking, it is critical that we expand our testing services to our large patient base in Oregon.” said Steven McAuley, Chairman & CEO of Empower.
The YES on the IP34 ballot initiative in Oregon has written that psilocybin-assisted therapy is different than the current mental health system; the focus is on treatment and health that doesn’t depend on a lifetime of pills. Rigorous studies at leading medical research institutions such as Johns Hopkins, UCLA, and NYU show that psilocybin is uniquely effective in treating depression, anxiety, trauma like PTSD and addiction. The FDA recently granted a “breakthrough therapy” designation – meaning that psilocybin-assisted therapy may demonstrate substantial improvement over what’s currently available.
“A major aspect of our new psychedelics division, Dosed Wellness, is assisting in the development of new legal markets from the ground up.” said Dustin Klein, SVP Business Development. “We are so pleased that our Portland clinic is a safe location to collect signatures for Oregon’s IP34 ballot initiative.”
Learn more about our new psychedelic’s division at www.dosedwellness.com
Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.
ON BEHALF OF THE BOARD OF DIRECTORS:
Chief Executive Officer
Chairman & CEO
SVP, Business Development
For French inquiries: Remy Scalabrini, Maricom Inc., E: email@example.com, T: (888) 585-MARI
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws.All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.